Themis Bioscience GmbH   Report issue

For profit Phase 1 Phase 2
Founded: Vienna Austria (2009)
Status: Acquired by Merck (2020)

Organization Overview

First Clinical Trial
2016
NCT02861586
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Themis Bioscience GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chikungunya Fever (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Infections (Phase 1)

Lassa Fever (Phase 1)

Virus Diseases (Phase 2)

Zika Virus Infection (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 11